Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Raises $5M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fluidigm, which refiled for an initial public offering last month, disclosed it has raised $5 million in an offering this month.

In a document filed on Thursday with the US Securities and Exchange Commission, the South San Francisco, Calif., microfluidic chip and instrument firm disclosed the raise was done through an offering of debt; options, warrants, or other rights to acquire another security; and securities to be acquired upon exercise of option, warrants, or other rights to acquire another security.

Fluidigm said the first date of the sale was Jan. 6, and $3,214 remains unsold from the offering. It did not disclose who the investors are.

The company refiled its IPO on Dec. 6. It has not provided a price range for its share or the anticipated number of shares it will offer. Fluidigm had previously filed for an IPO in 2008 but abandoned it later that year.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.